Denali Therapeutics Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $330.5M | $108.5M | $48.7M | $335.7M | $26.7M | $129.2M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $418.8M | $396.4M | $423.9M | $358.7M | $265.4M | $212.6M | $193.4M | $143.2M |
| SG&A Expense | $136.6M | $105.4M | $103.4M | $90.5M | $79.1M | $60.3M | $46.5M | $32.3M |
| Operating Income | $-555.3M | $-487.3M | $-196.7M | $-340.7M | $-295.8M | $62.7M | $-213.2M | $-46.4M |
| Operating Margin | — | — | -59.5% | -314.2% | -607.8% | 18.7% | -799.1% | -35.9% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | $102.0K | $68.0K | $30.0K | $21.0K | $-575.0K | $823.0K | $-351.0K | $0 |
| Net Income | $-512.5M | $-422.8M | $-145.2M | $-326.0M | $-290.6M | $71.1M | $-197.6M | $-36.2M |
| Net Margin | — | — | -43.9% | -300.6% | -597.2% | 21.2% | -740.7% | -28.1% |
| EPS (Basic) | $-2.97 | $-2.57 | $-1.06 | $-2.60 | $-2.39 | $0.65 | $-2.07 | $-0.39 |
| EPS (Diluted) | $-2.97 | $-2.57 | $-1.06 | $-2.60 | $-2.39 | $0.63 | $-2.07 | $-0.39 |
| Shares Outstanding (Basic) | 172.6M | 164.5M | 137.4M | 125.5M | 121.5M | 109.0M | 95.6M | 92.6M |
| Shares Outstanding (Diluted) | 172.6M | 164.5M | 137.4M | 125.5M | 121.5M | 112.7M | 95.6M | 92.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |